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Strengths and limitations of this study
 ► The key strength of this study is the linkage of can-
cer registrations to primary care data enhancing our 
understanding of the diagnostic pathway for pa-
tients with cancer.
 ► Comparing different groups of patients based on 
their presenting symptoms in primary care enables 
a focus on patients with symptoms similar to those 
being referred into England’s pilot Multidisciplinary 
Diagnostic Centres (MDCs) who do not currently 
have an urgent referral pathway.
 ► A limitation of this study is that it does not com-
pare patients presenting with symptoms that would 
trigger an urgent referral under the National Institute 
for Health and Care Excellence (NICE) guidelines to 
those who experience non- urgent referral symp-
toms; instead, it mirrors the referral criteria of the 
MDCs to describe diagnostic pathways for these 
patients.
 ► Symptoms recorded in our study in primary care re-
lied on accurate reporting.
 ► Not all MDC referral criteria could be included in our 
study, notably general practitioner intuition/patient 
concern which were not recordable in the data.
AbStrACt
Introduction Patients presenting to primary care with 
site- specific alarm symptoms can be referred onto urgent 
suspected cancer pathways, whereas those with non- 
specific symptoms currently have no dedicated referral 
routes leading to delays in cancer diagnosis and poorer 
outcomes. Pilot Multidisciplinary Diagnostic Centres 
(MDCs) provide a referral route for such patients in 
England.
Objectives This work aimed to use linked primary 
care and cancer registration data to describe diagnostic 
pathways for patients similar to those being referred into 
MDCs and compare them to patients presenting with more 
specific symptoms.
Methods This cross- sectional study linked primary care 
data from the National Cancer Diagnosis Audit (NCDA) 
to national cancer registration and Route to Diagnosis 
records. Patient symptoms recorded in the NCDA were 
used to allocate patients to one of two groups - those 
presenting with symptoms mirroring referral criteria of 
MDCs (non- specific but concerning symptoms (NSCS)) and 
those with at least one site- specific alarm symptom (non- 
NSCS). Descriptive analyses compared the two groups and 
regression analysis by group investigated associations 
with long primary care intervals (PCIs).
results Patients with NSCS were more likely to be 
diagnosed at later stage (32% stage 4, compared with 
21% in non- NSCS) and via an emergency presentation 
(34% vs 16%). These patients also had more multiple 
pre- referral general practitioner consultations (59% vs 
43%) and primary care- led diagnostics (blood tests: 57% 
vs 35%). Patients with NSCS had higher odds of having 
longer PCIs (adjusted OR: 1.24 (1.11 to 1.36)). Patients 
with lung and urological cancers also had higher odds of 
longer PCIs overall and in both groups.
Conclusions Differences in the diagnostic pathway show 
that patients with symptoms mirroring the MDC referral 
criteria could benefit from a new referral pathway.
IntrOduCtIOn
Earlier detection of cancer improves clinical 
outcomes and quality of life for patients with 
cancer, through improved treatment options 
and increased likelihood of survival. Patients 
in England who present to their general 
practitioner (GP) with site- specific ‘alarm’ 
symptoms are likely to be referred via an 
urgent pathway under the ‘Suspected Cancer: 
recognition and referral’ guidelines from 
the National Institute for Health and Care 
Excellence (NICE)1 and are subsequently 
monitored within the Cancer Waiting Times 
timeframes.2 This ‘Two Week Wait’ (TWW) 
diagnostic route refers to the 14- day target 
between referral and seeing a specialist.3 
However, previous studies have identified 
large proportions of patients with cancer 
diagnosed without having alarm symptoms 
in general practice in Denmark (52%),4 with 
similar proportions in the UK5 and higher 
rates in Norway (60%).6 7
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In England, for patients who present without such site- 
specific alarm symptoms warranting a TWW referral, 
it can be challenging for GPs to select the most appro-
priate referral pathway. Examples of such non- specific but 
concerning symptoms (NSCS) include unexplained weight 
loss, fatigue and some types of abdominal pain.8 Patients 
presenting with NSCS could therefore experience repeated 
referrals to different secondary care departments before a 
cancer diagnosis is confirmed. Overall, this could lead to 
unstructured and prolonged diagnostic pathways, which 
could negatively impact on outcomes, such as poorer 
survival,9 later stage9 or worse patient experience.10 Patients 
with less alarm/specific symptoms are more likely to be 
diagnosed via emergency presentations,11 which is itself 
associated with poorer outcomes.12 If diagnostic pathways 
for such patients could be improved, there is an opportu-
nity to improve outcomes.
A potential solution for these patients has been recently 
trialled and evaluated by the Accelerate, Coordinate and 
Evaluate (ACE) Programme, which is a joint initiative 
between Cancer Research UK, Macmillan Cancer Support 
and NHS England. The programme aims to achieve 
earlier cancer diagnosis. Wave 2 of the ACE Programme 
is evaluating whether Multidisciplinary Diagnostic 
Centres (MDCs) can support earlier and faster diagnosis 
of cancers/non- cancer conditions for patients with no 
clear urgent diagnostic pathway using a symptom- based 
approach to streamline diagnostic pathways for such 
patients. The MDCs aim to provide comprehensive diag-
nostics under the care of the same team to provide a more 
rapid diagnosis of cancer and other conditions.13 Similar 
programmes have been implemented in Denmark4 14 and 
Sweden.15 There is currently little evidence of whether 
unmet need exists for patients in England likely to be 
referred into the MDCs and how their diagnostic path-
ways compare with patients presenting with more specific 
symptoms.
The National Cancer Diagnosis Audit (NCDA)16 
provides an opportunity to explore rich primary care 
data for patients with cancer diagnosed in 2014 and when 
linked to cancer registrations and other health datasets 
held at the National Cancer Registration and Analysis 
Service (NCRAS), Public Health England, it can build 
a more complete picture of diagnostic pathways. Symp-
toms at presentation to the GP are recorded in the NCDA 
enabling comparison of groups of patients presenting 
with different kinds of symptoms.
The aim of this particular study was to use linked 
primary care data to provide understanding of any unmet 
need for patients similar to those being referred into the 
MDCs and to compare them with patients presenting 
with more specific symptoms, specifically focusing 
on factors which could lead to poorer outcomes such 
as stage and route to diagnosis. In addition, primary 
care intervals (PCIs) for both groups of patients were 
compared.
MethOdS
datasets
The NCDA was conducted using primary care data 
submitted from participating GP surgeries on a voluntary 
basis. Cancer registrations from 2014 in England were 
sent to these surgeries where primary care information 
was collated to create the NCDA. This included dates 
of presentation and referral, symptoms at presentation, 
primary care- led investigations and many others.16 Eighty- 
three per cent of participating surgeries completed over 
95% of patient NCDA data with over 17 000 cancers 
submitted in total. The Routes to Diagnosis (RtD) dataset 
is generated at NCRAS, using several linked health data-
sets to determine the most likely diagnostic route,17 
including emergency presentations, inpatient, TWW and 
routine GP referrals.
data linkage
The NCDA and RtD datasets were linked with cancer 
registration data at tumour level using tumour ID. 
Where a patient had multiple cancers (n=385), GPs were 
instructed to enter the same demographic and patient 
details, while submitting symptoms, investigations and 
interval data for each cancer separately.
Allocation to symptom groups
There were 84 distinct symptoms listed in the NCDA. To 
reflect patients being referred into the MDCs, the patients 
in the linked dataset were allocated to one of two groups 
depending on the symptoms at presentation to the GP 
within the NCDA dataset. The symptoms used to allocate 
patients were derived from the combined referral criteria 
to the MDCs18 and an additional common presenting 
symptom (Bowel habit change) of the MDCs. These 
symptoms are listed in table 1.
To be allocated to the NSCS group, patients could only 
have symptom(s) listed in table 1. If a patient had symp-
tom(s) listed in table 1 but in addition had one or more 
other symptom, usually triggering a TWW referral (eg, 
a lump, bleeding), they were allocated to the non- NSCS 
group. Patients with unknown symptoms in the NCDA 
were excluded; reasons for this could be due to screening 
(where GPs could not enter symptoms) or that the symp-
toms were not known to the GP.
The PCI was defined as the time from first relevant 
presentation to the GP to when the patient is referred 
into secondary care.19 The first presentation date in the 
NCDA was completed as the date when the patient first 
presented with symptoms ultimately attributed by the GP 
to the diagnosis of cancer.16
Cancer sites were categorised into the Cancer Waiting 
Times site specific grouping20 depending on their Inter-
national Classification of Disease v10 code. They are listed 
in the online supplementary information, table S1.
exclusions
Patients with no symptom information could not be 
allocated to one of the symptom- based groups and 
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Table 1 List of non- specific but concerning symptoms—
Multidisciplinary Diagnostic Centres (MDC) referral criteria 
and a common presenting symptom
Symptom Notes
Distention
Pallor
Abdominal pain
(upper, lower, NOS*)
*NOS (not otherwise specified)
Bowel habit change
Constipation
Diarrhoea
Nausea and/or vomiting
Fatigue
Weight loss
Back pain
New onset diabetes
Lymphadenopathy (generalised and localised)
Deep vein thrombosis
Loss of appetite
Chest pain
Chest infection
Jaundice† † For local reasons, this 
specific symptom was a 
referral symptom in one MDC 
project
Figure 1 Data exclusions and allocation to symptom- based 
analysis groups.
NCDA, National Cancer Diagnosis Audit; NSCS, non- 
specific but concerning symptoms.
were therefore excluded (n=3844) (figure 1). We also 
excluded cancers diagnosed via death certificate (n=13) 
or screening (n=14) in the RtD. Patients with PCIs of 
a negative value (n=218) or over 730 days (n=80) were 
excluded as in previous methodology.16 21
Statistical analysis
Comorbidities were recorded in the NCDA and catego-
rised by patient in our analysis. Frequencies and propor-
tions of patients by different sociodemographic and 
disease characteristics were described in the NSCS and 
non- NSCS groups. Differences between proportions in 
the two groups by characteristic were assessed by χ2 tests. 
The PCIs were also described by characteristic and NSCS/
non- NSCS group. Based on the distribution of the PCI 
and clinical advice, the interval was divided into less than 
and including 28 days and over 28 days for regression 
analysis to denote a longer PCI. We used multivariable 
logistic regression with longer PCI as the outcome vari-
able with sociodemographic and disease characteristics 
as explanatory variables (age group, sex, comorbidities, 
deprivation, route to diagnosis, cancer site and stage). 
The regression analysis was also stratified by NSCS/non- 
NSCS group. Analyses were conducted in Stata V.15.1.
Patient and public involvement
Data for this study are based on information collected by 
the NHS. Patients and the public were not involved in the 
development of this study.
reSultS
There were 17 042 cancers records in the NCDA linked 
to cancer registration data. Following exclusions, 2794 
(22% of remaining NCDA cohort) patients had only 
MDC symptoms recorded and were allocated to the NSCS 
group. 10 079 (78%) patients had at least one non- NSCS 
symptom and were therefore allocated to the non- NSCS 
group (figure 1). Table 2 shows frequencies of patients in 
each of the NSCS and non- NSCS groups by sociodemo-
graphic and disease characteristics along with the PCI for 
each group and characteristic. Table 3 describes pathway 
and disease characteristics and corresponding PCIs.
The NSCS group were older with the median (IQR) age 
in the NSCS group of 72 years (63–81) and 69 (58–78) 
in non- NSCS. There were higher proportions of the 
NSCS group in the two oldest age groups. All factors in 
table 2 (apart from sex) show that there were significantly 
different proportions in NSCS compared with non- NSCS. 
Higher proportions of the NSCS group resided in more 
deprived areas and had more comorbidities. There were 
higher proportions of the NSCS group diagnosed via 
emergency presentation and lower proportions in the 
TWW diagnostic route. Excluding unknown stage, 33% 
of NSCS group were diagnosed at stages 1 or 2, compared 
with 55% in the non- NSCS group, with correspondingly 
higher proportions of NSCS patients diagnosed at late 
stage (excluding unknown: stages 3 and 4: NSCS 67%, 
non- NSCS 45%).
PCIs were consistently longer in the NSCS group in all 
categories of characteristics and at all levels with a wider 
IQR, with only a couple of exceptions. Patients diagnosed 
via the emergency presentation route had the same PCI 
for both groups. Patients under 25 years in non- NSCS had 
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Table 2 Characteristics of non- specific but concerning symptoms (NSCS) and non- NSCS patients and primary care intervals 
(median and IQR)
Frequencies
P value*
Primary care interval (days)
NSCS Non- NSCS NSCS Non- NSCS
n (%) n (%) Median (IQR) Median (IQR)
Total 2794 (21.7) 10 079 (78.3) 12 (1–39) 3 (0–23)
Age group
  0–24 33 (1.18) 123 (1.22) <0.001 0 (0–47.5) 5 (0–29)
  25–44 105 (3.76) 712 (7.06) 13 (0–45) 0 (0–15)
  45–59 387 (13.85) 1865 (18.50) 13 (0–42) 1 (0–19)
  60–69 645 (23.09) 2439 (24.20) 14 (1–41) 5 (0–28)
  70–79 827 (29.60) 2759 (27.37) 13 (1–42) 4 (0–24)
  80+ 797 (28.53) 2181 (21.64) 9 (1–31) 3 (0–22)
Sex
  Male 1410 (50.47) 5191 (51.50) 0.331 11 (0–36) 7 (0–29)
  Female 1384 (49.53) 4888 (48.50) 13 (1–43) 0 (0–15)
Deprivation quintile
  1—least deprived 557 (19.94) 2227 (22.10) 0.050 11 (1–36) 3 (0–23)
  2 599 (21.44) 2182 (21.65) 13 (1–41) 3 (0–26)
  3 595 (21.30) 2182 (21.65) 11.5 (1–35) 2 (0–23)
  4 567 (20.29) 1900 (18.85) 11 (0–42.5) 2 (0–21)
  5—most deprived 476 (17.04) 1588 (15.76) 13 (0–41.5) 3 (0–24)
Comorbidities
  0 661 (23.66) 2787 (27.65) <0.001 9 (0–37) 1 (0–21)
  1 853 (30.53) 2993 (29.70) 13 (1–43) 3 (0–25)
  2 678 (24.27) 2289 (22.71) 13 (1–39) 3 (0–23)
  3+ 602 (21.55) 2010 (19.94) 13 (1–39) 4 (0–28)
Diagnostic route
  Emergency 
presentation
949 (33.97) 1623 (16.10) <0.001 5 (0–27) 5 (0–26)
  GP referral 681 (24.37) 2509 (24.89) 14 (1–44) 7 (0–31)
  Two Week Wait 802 (28.70) 4782 (47.45) 14 (3–42) 1 (0–17)
  Inpatient elective 60 (2.15) 171 (1.70) 9.5 (0–45) 5 (0–48)
  Outpatient 235 (8.41) 724 (7.18) 12 (0–45) 5 (0–29)
  Unknown 67 (2.40) 270 (2.68) 10.5 (0–27) 8 (0–45)
Stage
  1 290 (10.38) 2573 (25.53) <0.001 13 (0–42) 0 (0–15)
  2 357 (12.78) 1828 (18.14) 10 (0–39) 0 (0–14)
  3 444 (15.89) 1516 (15.04) 12 (1–38) 5 (0–28)
  4 897 (32.10) 2094 (20.78) 14 (1–42) 8 (0–35)
  Unknown/other 806 (28.85) 2068 (20.52) 10 (0.5–37) 5 (0–28)
*Significance test of proportions in NSCS/non- NSCS by characteristic.
GP, general practitioner.
longer PCIs than the NSCS group. PCIs were longer for 
every stage of disease at diagnosis in the NSCS group.
There were higher proportions of patients with multiple 
consultations and more primary care- led investigations 
(apart from urinary investigations) in the NSCS group, 
there was also a higher proportion where the GP felt that 
there was an avoidable delay to their diagnosis in this 
group (table 3). Patients could have more than one inves-
tigation, so significance testing was not undertaken on 
this element in table 3; however, the other characteristics 
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Table 3 Pathway characteristics of non- specific but concerning symptoms (NSCS) and non- NSCS patients and primary care 
intervals (median and IQR)
NSCS
n (%)
Non- NSCS
n (%) P value*
Primary care interval (days)
NSCS Non- NSCS
Median (IQR) Median (IQR)
Number of consultations before referral†
  1 792 (28.35) 4362 (43.28) <0.001 0 (0–4) 0 (0–1)
  2 742 (26.35) 2197 (21.80) 12 (5–25) 14 (6–30)
  3 356 (12.74) 882 (8.75) 28 (11–59) 30 (14–58.5)
  4 196 (7.02) 460 (4.56) 40 (21–73) 42 (20–88)
  5+ 353 (12.63) 761 (7.55) 58 (33–134) 76 (33–148)
Primary care- led investigations
  Blood tests 1589 (56.87) 3510 (34.82) 15 (4–45) 14 (3–41)
  Urinary 21 (0.75) 175 (1.74) 35 (8–69) 14 (5–38)
  Imaging 930 (33.29) 2176 (21.59) 23 (7–55) 21 (6–50.5)
  Imaging: X- ray 393 (14.07) 1330 (13.20) 21 (6–55) 18 (5–50)
  Imaging: CT 123 (4.40) 226 (2.24) 27 (7–53.5) 35 (16–76.5)
  Imaging: Ultrasound 513 (18.36) 818 (8.12) 28 (10–58) 24 (8–51)
  Imaging: MRI 32 (1.15) 61 (0.61) 35 (9–60) 33.5 (11–98)
  Endoscopy 95 (3.40) 152 (1.51) 38 (6–94) 11.5 (0–50)
  Endoscopy: Upper GI‡ 52 (1.86) 102 (1.01) 41 (7–95) 14 (0–50)
  Endoscopy: Colon 45 (1.61) 44 (0.44) 42 (5–108) 7 (0–73)
  Other 314 (11.24) 904 (8.97) 20 (6–50) 17 (4–49)
  None 712 (25.48) 4544 (45.08) 0 (0–12) 0 (0–2)
Avoidable delays?
  Yes 738 (26.41) 2215 (21.98) <0.001 30 (6–85) 21 (0–70)
  No 1825 (65.32) 7256 (71.99) 7 (0–25) 1 (0–14)
  Unknown 231 (8.27) 608 (6.03) 15 (0–42) 6 (0–36)
Cancer site
  Brain and CNS§ 16 (0.57) 208 (2.06) <0.001 64 (35–99) 3 (0–16)
  Breast 17 (0.61) 1614 (16.01) 15 (3–33) 0 (0–0)
  Colorectal 804 (28.78) 817 (8.11) 8 (0–36) 3 (0–25)
  Gynaecology 179 (6.41) 634 (6.29) 14 (3–35) 1 (0–19)
  Haematology 338 (12.10) 782 (7.76) 12 (1–38) 10 (1–35)
  Head and neck 12 (0.43) 527 (5.23) 18 (0–45) 3 (0–28)
  Lung 423 (15.14) 1427 (14.16) 14 (1–45) 14 (2–45)
  Sarcoma 28 (1.00) 121 (1.20) 12 (1–43) 12.5 (0–46.5)
  Skin <5 (<1%) 742 (7.36) N/A 0 (0–2)
  Upper GI‡ 551 (19.72) 750 (7.44) 10 (1–36) 5 (0–33)
  Urology 279 (9.99) 2256 (22.38) 15 (3–43) 10 (1–31)
  Other 145 (5.19) 201 (1.99) 9 (0–35) 6 (0–32)
*Significance test of proportions in NSCS/non- NSCS by characteristic.
†Excluding 0 consultations.
‡Upper gastrointestinal (GI).
§Central nervous system (CNS).
in table 3 had statistically significantly different propor-
tions in NSCS/non- NSCS with all p values<0.001. There 
were higher proportions of breast, head and neck, brain 
and CNS and urological cancers in the non- NSCS group. 
Median PCIs were the same in both groups for lung 
cancer, similar for sarcoma, but longer in the NSCS group 
for all other groupings.
The PCI was longer in the non- NSCS group for patients 
presenting more than twice before referral. There was 
variation in PCI by group for investigations, with longer 
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intervals in the NSCS group for most tests, the exception 
being CT. PCIs were longer in those with an avoidable 
delay in the NSCS group and longer in both groups where 
there was an avoidable delay to diagnosis.
Table S2 (online supplementary information) shows 
unadjusted and adjusted ORs of having a long PCI for the 
entire NCDA cohort (n=12 873) and stratified by NSCS 
(n=2974)/non- NSCS (n=10 079) group. In the entire 
NCDA cohort, after adjustment for age, sex, deprivation, 
comorbidities, route, stage and site, being in the NSCS 
group was associated with having a longer PCI (adjusted 
OR (95% CIs 1.24 (1.12–1.36)). Compared with TWW, all 
other routes had higher odds of longer intervals. Higher 
comorbidity scores were also associated with longer PCIs. 
Compared with colorectal cancers, patients with haema-
tological, lung, sarcoma, brain and CNS and urological 
cancers were more likely to have longer PCIs. When strat-
ified by NSCS/non- NSCS, comorbidity remained signifi-
cantly associated with longer PCIs for all scores in NSCS 
and only in the highest category in the non- NSCS group. 
Associations by diagnostic route remained significant 
with a similar pattern for both groups, with lower odds in 
the NSCS group. Breast cancers had lower odds of having 
longer PCI in only in the non- NSCS group and only lung, 
brain and CNS and urological cancers had higher odds 
in both groups of having longer PCIs compared with 
colorectal cancer.
dISCuSSIOn
Summary of main findings
This large study used existing data to examine patients 
with cancer who could have been eligible for referral 
to an MDC. It showed clear differences in such patients 
and those eligible for urgent suspected cancer referral, 
whereby the former experienced longer PCIs, had more 
primary care interactions, were more likely to be diag-
nosed at later stage and via emergency presentation.
Strengths and limitations
The use of primary care data linked with cancer registra-
tions enables a detailed picture of the diagnostic pathway 
for patients with cancer. Symptoms recorded in the 
NCDA provide a basis for examining different groups of 
patients.
The allocation into the NSCS and non- NSCS groups 
by symptom is a proxy for distinguishing between alarm 
and non- alarm symptoms in the NICE referral guidelines. 
An analysis of symptom groups with a true separation 
between alarm symptoms warranting a referral onto an 
urgent referral pathway and vague symptoms which do 
not would be very difficult. This is especially the case 
for symptoms where there are more than one recom-
mendation depending on other symptoms and patient 
characteristics (such as appetite loss, with five different 
recommendations and weight loss with 13 recommen-
dations). Such analysis would also require patient char-
acteristic information which is not all available in the 
NCDA- linked data. This study, however, focused on the 
MDC referral criteria and common presenting symptoms 
recorded at MDCs. Indeed, the aim of this work was to 
provide evidence of the possible diagnostic problems 
facing patients similar to those potentially eligible to go 
through the MDCs.
Not all MDC referral criteria were recorded in the 
NCDA, including GP intuition or patient/family concern, 
though it is unlikely that the inclusion of this would have 
changed the allocation to symptom groups. Additionally, 
not all of the non- specific symptoms in our allocation list 
are truly low risk, with jaundice being the most debatable, 
instead being an alarm symptom for particular cancers, 
and it is genuinely high risk for pancreatic cancer, though 
much lower for other cancers.22 23 Symptoms recorded 
in the NCDA were not necessarily complete and relied 
on accurate recording in primary care systems for those 
completing the NCDA to extract.16
Comparisons with the literature
Previous work using the NCDA has shown significant vari-
ation in the patient interval (symptom onset to presen-
tation) by different abdominal symptoms,24 and cohort 
studies have shown similar variation of different diag-
nostic intervals by symptoms for patients with colorectal,25 
lung26 and pancreatic cancer.27 Other studies using 
linked primary care data have found longer diagnostic 
intervals (from symptom presentation to diagnosis) for 
those presenting with non- alarm symptoms5 28 29 when 
compared with alarm symptoms patients. A previous 
study examining patients with lung cancer found longer 
PCIs for patients presenting with vague symptoms.30
Previous work on PCIs have shown variation in these 
intervals by cancer site,16 31 32 yet only one has focused on 
different symptom profiles of patients with lung cancer.30
Our study adds to this body of literature by examining 
the diagnostic pathways of patients diagnosed in England 
with a wide range of cancers presenting with NSCS.
Interpretation and implications
The lack of specific referral pathways for patients 
who present with non- specific symptoms is well 
described.33 34 Our work explains the problems facing 
patients who presented with non- specific symptoms, 
similar to those to be referred into the MDCs, with longer 
PCIs more primary care interactions. The higher propor-
tion of late stage disease in those presenting with NSCS 
may relate to the passing of time until the symptoms 
became more pronounced, leading to a cancer diagnosis 
at a later stage of disease, possibly via an emergency, 
which we show that NSCS patients are also more likely 
to experience. These patients have longer time intervals 
before referral to secondary care indicating the lack of 
clear referral route onto a specific urgent cancer referral 
pathway.
The association between certain sites (lung, urology) 
and longer PCIs was evident in both groups and overall, 
probably due, in part, to presenting symptoms.
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We have demonstrated patients presenting with NSCS 
who would fulfil the criteria for MDC referral take longer 
to reach a diagnosis than those likely to be referred on an 
urgent suspected cancer pathway. They also have higher 
proportions of late stage/emergency presentations. This 
study does not show that MDCs can expedite diagnosis, 
but indicates the problems facing patients diagnosed 
with cancer who present with non- specific symptoms, for 
which MDCs may be the answer. The results of the MDC 
evaluations will be published separately.
COnCluSIOn
Using national linked data, we have demonstrated that 
patients presenting with NSCS experienced longer time 
intervals before diagnosis, were more likely to be diag-
nosed via an emergency and at a later stage of disease, all 
of which are associated with poorer outcomes. An alterna-
tive diagnostic referral pathway for these patients should 
therefore be considered.
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